Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712348 · ClinicalTrials.gov registry record · Phase 3
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
A Phase 3 study of Gaucher Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
- 10
- Study locations
NCT00712348: Completed Phase 3 study of Gaucher Disease, sponsored by Pfizer.
NCT00712348 is a Phase 3 study of Gaucher Disease that has completed, run by Pfizer. The registered enrollment target is 31 participants, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00712348, a Phase 3 study of Gaucher Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
Conditions Studied
Interventions
- DRUG Taliglucerase alfa
Study Locations (10)
Other
- Rambam Medical Center - Haifa
- Shaare Zedek Medical Center - Jerusalem
- Sala de Hematologia, Hospital Universitario Miguel Servet - Zaragoza
- Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust - Cambridge
- Royal Free Hospital - London
Florida
- University Research Foundation for Lysosomal Storage Diseases, Inc. - Coral Springs
Georgia
- Department of Human Genetics, Emory University School of Medicine - Decatur
New York
- Neurogenetics, NYU at Rivergate - New York
Victoria
- Bone Marrow Transplant Service, The Royal Melbourne Hospital - Parkville
Ontario
- Mount Sinai Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT00712348 record still lists
NCT00712348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 1 intervention - of which Taliglucerase alfa is the first listed.
NCT00712348 lists 10 locations in 6 states (Other, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT00712348 about?
NCT00712348 is a clinical study titled "Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase". This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
What is the current status of trial NCT00712348?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2008-12. Estimated completion is 2013-05.
What conditions does trial NCT00712348 study?
This clinical trial studies the following conditions: Gaucher Disease.
What interventions are being tested in trial NCT00712348?
The interventions under investigation include: Taliglucerase alfa (DRUG).
Who is sponsoring clinical trial NCT00712348?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00712348 being conducted?
This trial has 10 study locations across Florida, Georgia, New York, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00712348's enrollment target sits among peer trials
31 7th of 13 higher than 7 of 13 other Gaucher Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gaucher Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
COMPLETED · Phase 3
-
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
RECRUITING
-
A Long-term Follow-up Study of Gaucher Disease
RECRUITING
-
Gaucher Disease Outcome Survey (GOS)
RECRUITING
-
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
RECRUITING
-
The GBA Multimodal Study in Parkinson's Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia